bdp 12 has been researched along with sw033291 in 1 studies
| Studies (bdp 12) | Trials (bdp 12) | Recent Studies (post-2010) (bdp 12) | Studies (sw033291) | Trials (sw033291) | Recent Studies (post-2010) (sw033291) |
|---|---|---|---|---|---|
| 62 | 7 | 14 | 16 | 0 | 15 |
| Protein | Taxonomy | bdp 12 (IC50) | sw033291 (IC50) |
|---|---|---|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] | Homo sapiens (human) | 0.0022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Antczak, MI; Dawson, D; Desai, AB; Fink, S; Geboers, S; Hu, B; Li, H; Markowitz, SD; Nishikawa, G; Ready, JM; Smith, J; Toda, K; Wang, X; Williams, NS | 1 |
1 other study(ies) available for bdp 12 and sw033291
| Article | Year |
|---|---|
Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration.
Topics: Animals; Colitis, Ulcerative; Dinoprostone; Hydroxyprostaglandin Dehydrogenases; Mice; Quinoxalines | 2022 |